Mayo Clinic and Washington University Join Noxopharm CEP-2 Sarcoma Trial

Highlights

- **Mayo Clinic and Washington University in St. Louis set to enrol patients in CEP-2 trial**
- **Four prestigious US cancer centres now participating in sarcoma trial**
- **Trial builds on knowledge previously published in peer-reviewed scientific journal**

Sydney 5 July 2022: Innovative biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce the addition of three US sites for its CEP-2 sarcoma study; Washington University in St Louis and two Mayo Clinic sites in Florida and Minnesota.

Mayo Clinic is one of the world's best-known medical providers, caring for more than 1.3 million US and visiting international patients every year. Its Rochester site in Minnesota was recently named the best hospital in the US in 2021-2022 by *US News & World Report* and is also in its top three for cancer care.

Washington University's School of Medicine in St. Louis is a leader in medical research, teaching and patient care, and is one of the largest recipients of funding from the US National Institutes of Health (NIH) for research and training.

The participation of Mayo Clinic and Washington University in the trial reinforces Noxopharm's ability to attract leading medical researchers, as the company continues its science-driven strategy of advancing its most promising therapies to key value inflection points.

The three new sites are in addition to the City of Hope Cancer Center, another of the top ranked cancer hospitals in the US, which is currently treating patients with Veyonda® and doxorubicin for metastatic soft tissue sarcoma (ASX Announcement 28 February 2022).

Noxopharm CEO Dr Gisela Mautner commented: "We are delighted to have such prestigious institutions participating in the CEP-2 trial investigating treatments for soft tissue sarcoma, a challenging cancer with few treatment options. It is our hope that we will identify an effective treatment to improve outcomes and quality of life for sarcoma patients worldwide."

The Phase 1 CEP-2 trial builds on the findings from CEP-1, as published in the peer-reviewed journal *Current Therapeutic Research* (ASX Announcement 30 April 2021). Additionally, Orphan Drug Designation has been granted by the US FDA for the use of Veyonda in the treatment of sarcoma (ASX Announcement 22 March 2022). Noxopharm will keep the market updated as the trial progresses.

-ENDS-

About the CEP-2 Trial
CEP-2 is a Phase 1, open-label, dose-escalation and dose-expansion study of Veyonda® administered to cohorts of patients being treated with doxorubicin for the treatment of metastatic soft tissue sarcoma. Approximately 30 patients in the United States with a range of soft tissue sarcomas are being enrolled to be treated with the Veyonda / doxorubicin combination as a first-line treatment. A number of major sites are participating in CEP-2. The first, the City of Hope Cancer Center in Los Angeles, has commenced treatment. Mayo Clinic, Rochester, Mayo Clinic, Florida, and Washington University are ready to start enrolling patients.

Soft tissue sarcomas are often fatal cancers, up to 50% of high-grade sarcoma patients develop metastases and die within 12 months. They are defined as a rare cancer, with fewer than 20,000 new cases diagnosed in the US in 2021. The CEP-Program is based on pre-clinical and clinical findings of Veyonda enhancing the anti-cancer effect of a number of standard chemotherapeutic agents.

The findings from the CEP-1 clinical trial have been published in *Current Therapeutic Research* in April 2021.

Veyonda has been granted US FDA Orphan Drug Designation (ODD) in the treatment of sarcoma. This confers a period of market exclusivity and a number of financial and regulatory benefits.

About Noxopharm Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its lead clinical-stage drug candidate Veyonda®, plus two innovative technology platforms Chroma™ (oncology) and Sofra™ (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.